Crowdonomics
WatchlistPortfolio
All companies
DeoBioSciences logo

DeoBioSciences

Operating

DEOBIOSCIENCES INC

Biotech · Founded 2000

Visit website

DeoBioSciences is developing a treatment against advanced metastatic cancer for people and pets.

Post-money valuation ⓘ
$15.7M
As of Mar 2022 · from Reg CF Offering (2021) · pre-money + amount raised, not a traded price
Total raised
$110,350
Across 1 round since 2021
Latest share price
$50.00
Reg CF · Common Stock · Mar 2021 offering price

Financials

FY2018–FY2021 · from SEC filings · hover any figure for its source
$0
−$13K
2018
$0
−$15K
2019
$0
−$19K
2020
$0
−$47K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 reviewed
FY2019 reviewed
FY2020
FY2021
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$12,997
-$14,658
-$19,427
-$47,287
Taxes paid
$0
$0
$0
$1,677
Balance sheet
Cash
$74
$79
$1,151
$1,043
Accounts receivable
$0
$0
$0
$0
Total assets
$74
$79
$1,151
$1,043
Short-term debt
$2,962
$2,962
$4,035
$3,927
Long-term debt
$211,498
$226,161
$245,588
$292,873
Total liabilities
$214,460
$229,123
$249,623
$296,800
Other
Headcount
—
1
—
1

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$15.6M
pre-money
Reg CF · Common · Mar 2021

Blue bars are the pre-money valuation the company stated for a priced round.

Fundraising history

Reg CF · Common Stock · Mar 2021Closedvia Netcapital
Raised $110.4K / $1.1MPost-money $15.7M

Team

3 people
Catherine Bryant
Board Member
John Adamson, Jr.,
Principal Executive Officer
Kathyrn Smith
Board Member

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 1 of 6 annual reports (FY2020–FY2025)

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

View all 11 filings on EDGAR
  • Form C-TRApr 24, 20230001523215-23-000001
    EDGAR
  • Form C-ARApr 28, 20220001669191-22-000441
    EDGAR
  • Form C-UApr 4, 20220001669191-22-000353
    EDGAR
  • Form C/AJan 26, 20220001669191-22-000058
    EDGAR
  • Form C/ANov 23, 20210001669191-21-001152
    EDGAR
  • Form C/AOct 8, 20210001669191-21-001021
    EDGAR
  • Form C/ASep 24, 20210001669191-21-000957
    EDGAR
  • Form C/AJul 27, 20210001669191-21-000723
    EDGAR
Source: ManualCIK 0001523215Share price $50.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.